Titan Pharmaceuticals, Inc. (de)
TTNP
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.11M
Close$
$3.15
34.6% upside
Current Fair Value
34.6% upsideUndervalued by 34.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.11 Million |
|---|---|
| Enterprise Value | $1.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.23 |
| Beta | 1.38 |
| Outstanding Shares | 1,398,000 |
Return
| Return on Equity | -143.32% |
|---|---|
| Return on Assets | -124.40% |
| Return on Invested Capital | -133.75% |
Valuation & Multiples
| P/E Ratio | 17.09 |
|---|---|
| PEG | 326.03 |
| Price to Sales | - |
| Price to Book Ratio | 2.34 |
| Enterprise Value to Revenue | 115.77 |
| Enterprise Value to EBIT | -0.44 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
January 1, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 2.09% |
|---|---|
| Total Invested | $154▼ 99.86% |
| Investors Holding | 4▼ 13.00% |
ESG Score
No data
About Titan Pharmaceuticals, Inc. (de)
12 employeesTitan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potentia...